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ICPLThe pp32 (ANP32A) gene acts as a tumor suppressor while its closely related homologue pp32r1 (ANP32C)
is oncogenic and is overexpressed in breast, prostate and pancreatic tumors. The transduction of p53wt cell
lines (ACHN and HeLa) with pp32r1 or pp32r1Y140H lentivirus increased the proliferation of p53wt cell
lines compared to the untransduced control cells while transduction of the p53R248W MiaPaCa2 cell line
had no effect. Cell cycle analysis of transduced ACHN cells by PI staining and BrdU incorporation illustrated
a pronounced shift toward the S-phase of the cell cycle in cells overexpressing the pp32r1 and
pp32r1Y140H proteins. Confocal microscopy and western blotting demonstrated that pp32r1 and the
pp32r1Y140H mutant protein reside predominantly in the cytoplasm in constrast to pp32 which is a
nuclear/cytoplasmic shuttling protein. To determine the effects of pp32r1 or pp32r1Y140H overexpression
at the proteomic level we performed a comprehensive proteome analysis on ACHN, ACHN-pp32r1 and
ACHN-pp32r1Y140H cell lysates using the isotope-coded protein label (ICPL) method. Among those pro-
teins with >40% regulation were Macrophage Capping protein (CAPG) and Chromodomain Helicase DNA
binding protein 4 (CHD4) proteins which were signiﬁcantly upregulated by pp32r1 and pp32r1Y140H
overexpression. This increase in CHD4 also appears to inﬂuence a number of cell cycle regulator genes in-
cluding; p53, p21 and cyclinD1 as judged by western blotting. Silencing of CHD4 in ACHN-pp32r1Y140H
cells using speciﬁc shRNA reverted the cell cycle dysregulation caused by pp32r1Y140H expression to
that of the untransduced ACHN cell line, suggesting that CHD4 is the prominant effector of the pp32r1/
pp32r1Y140H phenotype.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Pp32 (ANP32A) is a well characterized multifunctional protein
that regulates transcription, apoptosis and cell cycle progression
through the Inhibitor of Acetyl Transferase activity (INHAT), SET
and Retinoblastoma protein (pRb) complexes that all contain pp32
[1,2]. While pp32 itself acts as a tumor suppressor its close homo-
logue pp32r1 (ANP32C) is oncogenic and found to be overexpressed
in poorly differentiated tumors, but not in normal cells [3,4].
Interestingly, pp32r1 has also been suggested to be highly
expressed in activated stem cells including mobilized CD34+
peripheral blood cells and CD34+ cord blood cells but not inicine,HannoverMedical School,
49 511 532 9710; fax: +49 511
Huyton).
l rights reserved.resting CD34+ bone marrow cells [3]. The functional role of
pp32r1 at present is unclear and despite the high sequence homol-
ogy between pp32 and pp32r1 (~87%), pp32r1 is unable to substi-
tute for pp32 in some situations as is demonstrated by its inability
to associate with retinoblastoma protein [2]. Some functionality
‘sharing’ however is likely to occur between the pp32 family mem-
bers (ANP32A-H) [4] since pp32 knockout mice have no distinct
phenotype [5].
Structurally the 28-kDa pp32 family of proteins contain several
functional domains; a capped LRR motif at the N-terminus [6] a
central domain (amino acids 150–174) containing the region
required for cellular transformation [7] and a highly acidic C termi-
nus containing ~70% aspartic and glutamic acid residues [8]. A func-
tional mutation in pp32r1 comprising a Y140H substitution has been
characterized and is associated with the rapid growth of the prostate
cancer cell line PC-3 fromwhere it was identiﬁed, furthermore trans-
fection of this mutated gene construct into cell lines demonstrated
striking increases on cell proliferation rates [3].
In this work we sought to further characterize the effects of pp32r1
and the pp32r1Y140H functional mutant in cells and investigate the
mechanism by which it dysregulates the cell cycle.
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2.1. Lentiviral vector constructs
Genomic DNA was isolated from ~5×106 HeLa cells using a
Nucleospin genomic DNA isolation kit (Machery-Nagel). A 1 Kb
pp32r1 (PP32R1) genomic fragment was ampliﬁed by PCR using
this genomic DNA as the template. The pp32r1 ORF was then ampli-
ﬁed using speciﬁc primers using the gemomic PCR fragment as a
template and the resulting 702 bp PCR product was ligated in the
eukaryotic expression vector pcDNA3.1 V5/His TOPO (Invitrogen,
Karlsruhe, Germany). A lentiviral vector construct was then gene-
rated by subcloning the BamHI/XbaI fragment of the pcDNA3.1-
pp32r1-V5HIS construct into the lentiviral pRRL.PPT.SFFV.mcs.pre
vector [9] to generate pRRL-pp32r1-V5HIS.
The pRRL-pp32r1Y140H-V5HIS mutant construct was generated
using the Quickchange mutagenesis kit (Stratagene) according to
the manufacturers protocol using the following oligonucleotide
sequences; Y140H_sense 5′-ttctcctgcaactcacacatctcgacagctgttac-3′,
Y140H_antisense 5′-gtaacagctgtcgagatgtgtgagttgcaggagaa-3′. Wild
type and mutant constructs were both sequence veriﬁed using an
ABI PRISM 377 sequencer (Applied Biosystems, Foster City, CA,
USA).
2.2. Virus production in HEK293T cells
HEK293T cells were transfected essentially as described [10] with
5 μg Plasmid DNA (packaging plasmid: psPAX2; envelope plasmid:
pDM2G) inDMEMmedia (Invitrogen) using Lipofectamine (Invitrogen).
Transfected HEK293T cells were incubated for 24 h before replacing the
cell culture media. 48 h post-transfection, virus-containing supernatant
was removed, passed through a 0.45 μm ﬁlter (Millipore GmbH,
Schwalbach, Germany) and centrifuged for ~12 h (16 °C, 10.000 rpm).
The Lentiviral-pellet was then dissolved in DMEM (Invitrogen) and
used directly for transduction.
2.3. Cell culture, lentiviral transduction and cell growth assays
ACHN, Hela and MiaPaCa2 cells were grown at 37 °C in a 5%
CO2-humidiﬁed atmosphere in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 50 U/mL penicillin, 50 μg/mL strepto-
mycin, 2 mM L-glutamine, 1% NEAA, 1 mM Sodium Pyruvate and
10% fetal bovine serum (FBS). For lentiviral transduction 5×106
cells were plated in 10-cm tissue culture plates. The following day
transduction of cells was then performed by adding the dissolved
lentiviral-pellet to the cells in the presence of 8 μg/mL protamine
sulfate (Sigma-Aldrich) followed by incubation for 8 h. Control
pRRL-GFP lentiviral particles were used to monitor the transduction
efﬁciency for the various cell types.
For cell growth assays 5×105 cells were plated in 10-cm tis-
sue culture plates and incubated for 6 days. Cells were then
ﬁxed and stained with a solution of 0.2% methylene blue in
50% methanol.
2.4. Evaluation of pp32 and pp32r1 mRNA levels by real-time RT-PCR
Total cellular RNA was isolated from cells using the RNeasy Mini
Kit (Qiagen, Hilden, Germany), those samples used to measure
pp32r1 gene expression levels were treated with DNase to prevent
genomic ampliﬁcation since pp32r1 is an intronless gene. RNA
(1 μg) was transcribed into cDNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) according to the
manufacturer's protocol. qRT-PCR using the appropriate speciﬁc
TaqMan assay kit (Supplementary Table 1, Applied Biosystems,
Darmstadt, Germany) was carried out on a StepOne Plus Real-Time
PCR System (Applied Biosystems) with thermal cycling conditionsof 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles
at 95 °C for 15 seconds and 60 °C for 1 min. GAPDH or β-actin
mRNA (as speciﬁed) was ampliﬁed as a reference standard for
normalization of mRNA levels and all reactions were performed in
triplicate. The Relative CT Method (described in the User Bulletin
No. 2, ABI PRISM 7700 Sequence Detection System, pp. 11–15) as
implemented in the steponeplus software was used to calculate
the relative mRNA level of the assay gene normalized to GAPDH or
β-actin in each sample. All values are expressed as fold-changes
relative to their appropriate control (set to 1.0).
2.5. Transfection of cells with shRNA
Cells were plated into 6 well plates in 2 ml culture media
at cell numbers to achieve 50–70% conﬂuency the next day. Trans-
fections were carried out using Lipofectamine 2000 reagent (Invitrogen)
as per the manufacturer's protocol. CHD4 shRNAs were from OriGene —
vector control, scrambled shRNA (scr) control, shRNA#1, shRNA#2,
shRNA#3 and shRNA#4. The highest knockdown efﬁciency was seen
with shRNA#1 and shRNA#1+#2 combined and these were se-
lected for further studies.
2.6. Confocal Laser Scanning Microscopy (CLSM)
HEK293T cells were plated on coverslips in 6 well plates and
transfected with pcDNA3.1⁄CT-GFP-TOPO (Invitrogen) containing
pp32r1-GFP and pp32r1Y140H-GFP. 72 h post transfection cells were
ﬁxed with 4% p-formaldehyde, stained with the nuclear stain DAPI
and imaged on a Leica DMIRE2 system using 405 nm and 488 nm
laser lines. Brightﬁeld imageswere simultaneously acquired. All images
were acquired with 63X oil immersion lens, zoom 3.00 and processed
using Image J software.
2.7. SDS-PAGE/Western blotting
Whole cell lysates were obtained using RIPA lysis buffer containing
Na2VO3 and NaF (when speciﬁed) Protein quantitation was performed
using a BCA assay (Uptima). For Nuclear/Cytoplasmic localization ex-
periments cells were lysed using the ProteoJet cytoplasmic and nuclear
protein extraction kit (Fermentas) according to the manufacturer's
protocol. Proteins were separated using 4%–12% Bis–Tris polyacryl-
amide gels (Invitrogen) and were transferred to PVDF membrane
using an iBlot (Invitrogen) before blocking and incubation with speciﬁc
antibodies (Supplementary Table 2).
2.8. Cell cycle analysis
The cell cycle distribution of the three cell lines was analyzed
by using propidium iodide (PI)-staining. Brieﬂy, 1×106 cells were
trypsinized and washed with PBS and permeabilized with 70% etha-
nol. Cells were washed again with PBS and then stained with,
200 mg/mL RNase A (Sigma) and 50 mg/mL propidium iodide
(Sigma) before analysis on a FACSCanto ﬂow cytometer (BD biosci-
ence). Single cell populations were gated, as judged by PI-A vs PI-W,
and the percentage of cells in the various stages of the cell cycle
was determined using Flowjo (Treestar, Inc) implementing the
Watson (pragmatic) model. Three independent experiments were
performed for each cell line, a representative of which is shown.
2.9. S phase analysis
BrdU incorporation assay (BrdU-FITC/7-AAD kit, Becton Dickinson)
was performed on all 3 cell lines according to the manufacturer's proto-
col. Cells were incubated with 10 μM BrdU for 30 min. Labeled cells
were harvested, ﬁxed, permeabilized, neutralized and BrdU detected
using a FITC labeled mouse anti-BrdU antibody. Cells were then
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tent were analyzed using a FACSCanto ﬂow cytometer (BD bioscience).
2-D cell cycle analysis (FITC Vs 7-AAD) was carried out using Flowjo
(Treestar, Inc).2.10. ICPL
ICPL labelling and mass spectrometry was carried out by Toplab
GmbH (Martinsfried, Germany) using the protocol as described by [11].
A total of 1–2×106 ACHN, ACHN-pp32r1 transduced, and ACHN-
pp32r1Y140H transduced cells were harvested from 70% conﬂuent
plates and washed thoroughly with PBS. Cells were then lysed and
equal protein amounts for the three different samples were labeled
with ICPL triplex, and multiplexed. The SERVA protein standard com-
posed of three proteins in known ratios was added to control the label
efﬁciency. The samples were then reduced, alkylated, cleaved with tryp-
sin and GluC, and analyzed by high resolution LC-ESI-MS/MS using an
LTQ-Orbitrap (Thermo Scientiﬁc). The acquired MS/MS spectra were
then searched against the human Swiss-Prot and the NCBI databases
using MASCOT [12].
Database queries were performed using Mascot software
[12] implementing the IPI human and the respective decoy
databases.
After the ﬁrst LC-ESI-MS/MS run an inclusion list of unidentiﬁed
regulated proteins was generated and used for a second LC-ESI-MS/
MS run to increase the number of identiﬁed regulated proteins.
Data evaluation, interpretation, and quantiﬁcation were performed
using the ICPLQuant software (MPI for Biochemistry) [13] that
sums the two LC-MS/MS runs for the experiment. Additionally we
performed a reference set sample where equal amounts of each of
the three samples were pooled together, then split into three equal
aliquots and labelled with the light, medium, and heavy ICPL label,
respectively, this enables detection of all triplets possible and was
included in the subsequent ICPL Quant data analysis.Fig. 1. Expression of pp32 or pp32r1Y140H leads to increased cell growth in cancer cel
untransduced and transduced ACHN, HeLa and MiaPaCa2 cell lines by western blotting of
as loading control. (B) Cell growth assays 5×105 cells were plated in 10-cm tissue culture
0.2% methylene blue in 50% methanol.3. Results
3.1. Generation of cancer cell lines overexpressing pp32r1 or
pp32r1Y140H mutant proteins
The renal cancer cell line ACHN, cervical cancer cell line HeLa and
pancreatic cancer cell line MiaPaCa2 were lentivirally transduced
with constructs encoding either pp32r1 or the pp32r1Y140H func-
tional mutant as described in the materials and methods. Stable
cell lines were then generated by limiting dilution with selection
based upon protein expression as judged by western blotting
against the V5 epitope tag on the recombinant pp32r1 proteins.
The various cloned cell lines showed high expression of pp32r1
and pp32r1Y140H proteins as illustrated in Fig. 1a. These cell lines
were subsequently used in all additional experiments.3.2. Characterization of the cell growth and cell cycle modulation in
pp32r1 and pp32r1Y140H overexpressing cancer cell lines
We observed as was previously described [3] that pp32r1Y140H
expressing ACHN cells grew much faster compared to ACHN or
pp32r1 expressing cells. To visualize the differences in proliferation
rates of the transduced ACHN, HeLa and MiaPaCa2 cell lines we
plated them out at low conﬂuency (5×105 cells per 10 cm dish)
and grew them for 6 days before ﬁxing and staining with methylene
blue. While the p53wt cell lines (ACHN and HeLa) demonstrated
pronounced increases in proliferation upon overexpression of
pp32r1 or pp32r1Y140H mutant proteins the transduced p53R248W
MiaPaCa2 cell line showed no differences in cell growth (Fig. 1b).
To further investigate this phenomenon we performed compara-
tive cell cycle analysis on the ACHN cell lines using propidium iodide
(PI) staining. Control ACHN cells showed a cell cycle distribution
containing 13.7% of cells in the S-phase of the cell cycle, while cells
transduced with pp32r1 or the Y140H mutant showed 15.4% andl lines. (A) Determination of pp32r1 and pp32r1Y140H protein expression levels in
cell extracts with an anti-V5 tag antibody, the housekeeping protein GAPDH was used
plates and incubated for 6 days. Cells were then ﬁxed and stained with a solution of
Fig. 2. Cell cycle analysis: Flow cytometry analysis of propidium iodide stained cells to illustrate the percentage of cells in each phase of the cell cycle (A, C, E) and BrdU incorpo-
ration (B, D, F) to determine the percentage of cells in the S-phase of the cell cycle A–B) ACHN, C–D) ACHN-pp32r1 and E–F) ACHN-pp32r1Y140H cell lines.
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conﬁrm these results a BrdU incorporation assay was performed
and these results are illustrated in Fig. 2b, d, f, while Supplementary
Table 3 summarizes the results of both Cell cycle and S phase
analysis.
In both experiments we observed a 2-fold increase in S phase
of pp32r1Y140H expressing ACHN cells relative to ACHN and
pp32r1 expressing cells, reﬂecting the increased proliferation rate
in these cells.
Control HeLa cells showed a cell cycle distribution containing
12.4% of cells in the S-phase of the cell cycle, while cells transduced
with pp32r1 or the Y140H mutant showed increases to 13.2% and16.2% respectively in the S-phase of the cell cycle (Supplementary
Fig. 1a). In contrast to ACHN and Hela cells control and transduced
MiaPaCa2 cells showed very similar S-phase statistics with 18.8%,
19.1% and 20.5% S-phase cells (Supplementary Fig. 2a).
3.3. Characterization of the subcellular localization of pp32r1 and
pp32r1Y140H proteins by confocal microscopy
The structural and functional differences between the ANP32
family members (ANP32A–H) are still unclear, however the cellular
localization of individual family members has been attributed to a
Nuclear localization sequence (NLS) at the extreme C-terminal of
Fig. 3. Sub-cellular localization of pp32r1 and pp32r1Y140H proteins: Confocal Laser Scanning Microscopy (CLSM) analysis of HEK293T cell line transiently over expressing
GFP-tagged pp32r1 or pp32r1Y140H a-b) Bright ﬁeld (BF), c–d) DAPI nuclear stained, e–f) GFP, g–h) DAPI-GFP overlay.
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the NLS appears incomplete with only the residues KRK at the
C-terminus, we therefore sought to determine and compare the
cellular localization of pp32r1 and the pp32r1Y140H mutant pro-
tein. We performed Confocal Laser Scanning Microscopy (CLSM) on
HEK293T cells transiently overexpressing C-Terminal GFP tagged
pp32r1 and pp32r1Y140H constructs. The localization of both
pp32r1 and mutant proteins was observed to be predominantly cy-
toplasmic and is shown in Fig. 3. To further conﬁrm these results,
we performed immunoﬂuorescence microscopy on our ACHN cell
lines stably overexpressing pp32r1 and pp32r1Y140H. Since the pro-
tein sequences for pp32 and pp32r1 are ~87% identical we ﬁrst
checked by ELISA (using recombinant bacterially produced pp32
proteins) that the commercial antibodies against pp32 and pp32r1
were speciﬁc (Supplementary Fig. 3A). The pp32r1 antibody was
highly speciﬁc and able to react with pp32r1 and pp32r1Y140H
proteins but showed no reactivity toward pp32 protein. We then
performed immunoﬂuorescence with the pp32r1-speciﬁc antibody
on ﬁxed cells using DAPI as a nuclear stain. Although staining was
quite weak it could clearly be seen that the expression pattern
of pp32r1 and the pp32r1Y140H proteins was predominantly cyto-
plasmic (Supplementary Fig. 3B). Additional western blotting of
cytoplasmic and nuclear extracts (Supplementary Fig. 3C) demon-
strated that both pp32r1 and pp321Y140H are predominantly cyto-
plasmic, in contrast to the known nuclear/cytoplasmic shuttling
seen with pp32 [14].3.4. Proteome analysis — ICPL strategy
We sought to identify potential differences between the three
cell lines that could explain the altered proliferative capacity and
cell cycle changes by performing a comprehensive proteomic
analysis using an ICPL strategy (Full quantitated ICPL results are
given in Supplementary Excel Table 1). From these mass spectrom-
etry data we were able to identify a number of proteins that show
a signiﬁcant regulation (>40%) relative to the wild type ACHN cell
line and these are listed in Table 1. The CAPG and CHD4 proteins
showed more than 1.5 fold upregulation and were selected to
validate the results of the ICPL by QRTPCR and western blotting.3.5. Regulation of CAPG and CHD4 expression in ACHN cell lines transduced
with pp32r1 or the Y140H mutant
To conﬁrm the regulation of expression for the CAPG and CHD4
proteins that were shown to be upregulated in our ICPL results we
assessed the mRNA levels by qRT-PCR using Taqman assays and
protein levels by western blotting of cell lysates. At the mRNA level
no signiﬁcant changes in the mRNA levels of either the CAPG or
CHD4 genes were observed in the transduced cell lines (Fig. 4a). In
contrast western blotting of ACHN and transduced cell lysates with
CAPG and CHD4 speciﬁc antibodies demonstrated that both proteins
are upregulated (Fig. 4b). CAPG upregulation was estimated from
average band intensity values to be increased ~1.6-fold for both
pp32r1 and pp32r1Y140H lysates and was comparable with the
ICPL data. The detection of endogenous CHD4 in untransduced cells
proved difﬁcult to detect, likely due to the low expression levels
and poor blotting efﬁciency of the large 218Kda protein. This expres-
sion however became highly upregulated in cell lines overexpressing
pp32r1 or the pp32r1Y140H proteins (Fig. 4b).
Increased CHD4 and p21 expression in the pp32r1/pp32r1Y140H
transduced HeLa cell lines was also observed (Supplementary Fig. 1b).
However in the MiaPaca2 cell lines which contain the common
p53R248W mutation all p53 dependent p21 expression is abolished,
thus no detectable p21 by western blotting (Supplementary Fig. 2b).
In these cell lines CHD4 was difﬁcult to detect due to low endogenous
levels, however slight increases were also observed in cells expressing
pp32r1 and pp32r1Y140H proteins (Supplementary Fig. 2b).
3.6. Delineation of the CHD4 pathway mediating the G1/S phase
dysregulation
CHD4 has been shown to play a major role in the coordination of
the DNA Damage Response (DDR) and its expression level appears to
be a critical regulator of the G1/S transition phase of the cell cycle
through its inﬂuence on the p53–p21 axis of the cell cycle [15].
We therefore compared ACHN, ACHN pp32r1 and pp32r1 mutant
overexpressing cell lines to ascertain if there were differences at
the mRNA and protein levels for the cell cycle regulatory genes;
retinoblastoma (Rb)/phosphorylated retinoblastoma (P-Rb), Acetylated
p53 (p53Ac), p21, cyclinD1 and cyclinE. From Fig. 5b, p21 and cyclinD1
Table 1
ICPL data-proteins illustrating signiﬁcant regulation.
Protein Status and Fold change in
expression relative to wild
type ACHN cell line
Oncogenic role
pp32r1 pp32r1 Y140H
Serum albumin (ALBU) 2.61 ↑ 3.51 ↑ • Immune suppression via the delivery of immune inhibitory molecules
into the tumor microenvironment [32].
Keratin type I cytoskeletal 18 (K1C18) 0.54 ↓ 0.64 ↓ • Epithelial to mesenchymal transition, higher mitotic rate, metastasis,
and poor prognosis in primary breast carcinoma [33]
Lamin B1/B2 (LMNB1/B2) 1.52 ↑ 0.97↔ • Marker of increased anti-apoptotic signaling [34]
60S Ribosomal protein (RL23) 2.29 ↑ 3.94 ↑ • Multidrug resistance in gastric cancer [35] and [36]
Superoxide dismutase (SODC) 1.84 ↑ 0.73 ↓ • Elevated levels an indicator of poor prognosis [37]
• Decreased levels in prostate cancer may be carcinogenic due to higher
incidence of mutations [38,37]
Eukaryotic translation initiation factor
3 M (EIF3M)
0.905↔ 0.62 ↓ • Down regulated in some cancers, including prostate cancer
(Wooster, R et al.; accession: E-MTAB-37)
Ubiquitin 40S ribosomal protein (RS27A) 0.99↔ 0.62 ↓ • Generates free ubiquitin monomer, that on conjugation to a target protein
has a role in DNA repair/cell-cycle regulation/protein degradation via the
proteasome [39,40]
Macrophage Capping protein (CAPG) 1.33↔ 1.56 ↑ • Malignant phenotype in Oral Squamous Cell Carcinomas (OSCCs), Endometrial
carcinoma (EmCa), Pancreatic Ductal Adenocarcinoma, Prostate cancer [17–20]
Chromodomain Helicase DNA binding
protein 4 (CHD4)
1.36↔ 1.53 ↑ • Coordination of repair events after DNA double strand breaks (DSBs) and cell
survival signaling [21,22]
High mobility group protein (HMGA1) 0.8↔ 0.65 ↓ • Decreased levels have a negative impact on the role of p53 as tumor suppressor
and ability of progesterone to inhibit the growth of solid tumor [41,42]
Vimentin (VIME) 0.775↔ 0.55 ↓ • Contrary to published data (See text)
Heat shock cognate (HSP7C) 0.835↔ 0.6 ↓ • Contrary to published data (See text)
Mitochondrial Stress 70 protein (GRP75) 0.74↔ 0.65 ↓ • Contrary to published data (See text)
↑ = upregulated (>40%); ↓ = downregulated (b40%);↔= no signiﬁcant regulation.
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phosphorylated retinoblastoma (P-Rb) no difference in protein levels.
At the RNA level, while p53 showed no difference in levels, p21 was
downregulated (Fig. 5a)
3.7. CHD4 shRNA mediated knockdown
We have shown that CHD4 is upregulated as a result of the
overexpression of pp32r1Y140H (Fig. 4b) and that prominent cell
cycle regulatory genes were subsequently affected (Fig. 5b). We
next performed knockdown of CHD4 using shRNA containing vectors
to determine if the increase in CHD4was indeed the main cause of the
observed G1/S phase dysregulation in the ACHN pp32r1Y140H cell
line. Cells were transfected with shRNA containing vectors speciﬁc
for CHD4, selected with puromycin and compared to empty vector
and shRNA-scramble (scr) controls. We observed a knockdown
of~50% with shRNA# 1 and~48% with shRNA#1+#2 combined,
compared to the shRNA-scrambled control (Supplementary Fig. 4a).
Subsequent PI based cell cycle analysis of the CHD4 knockdown
cells showed a signiﬁcant reduction in the S phase by~80% and
appears to revert the cell cycle proﬁle of pp32r1Y140H over-expressing
cells to that of the untransduced ACHN cell line (Supplementary Figs. 4b
and 2).We again checked themRNAandprotein levels of retinoblastoma
(Rb)/phosphorylated retinoblastoma (P-Rb), Acetylated p53 (p53Ac),
p21, cyclinD1 and cyclinE across the four ACHN pp32r1Y140H trans-
fected cell lines— vector, scrambled, shRNA#1 and shRNA#1+#2 com-
bined. As seen in Fig. 6b, reduced CHD4 protein levels corresponded to a
concomitant increase in p53Ac382 levels; however, p21 levels still
remained elevated despite the CHD4 knockdown. At the mRNA level
(Fig. 6a), negligible change was seen in case of p53, while p21 showed
decreased levels. This trend has previously been reported in other
transformed cell lines [16].
4. Discussion
The pp32 (ANP32A) protein acts as a tumor suppressor while its
closely related homologue pp32r1 (ANP32C) exhibits an opposingfunction by acting as an oncogenic mediator. In this study we sought
to fully characterize the effects of overexpressing pp32r1 or its function-
al mutant pp32r1Y140H in several cancer cell lines.
The pp32 protein sequence contains a Nuclear Localization Signal
(NLS) and is predominantly localized in the nucleus, although it has
been recently shown to shuttle between nucleus and cytoplasm
alongside HuR [14]. In contrast the sequence of pp32r1 (and its mu-
tant) contains an incomplete NLS, which suggested cytoplasmic
localization. To conﬁrm this we performed both Fluorescence micros-
copy on HEK293T cells transiently overexpressing C-Terminal GFP
tagged pp32r1 and pp32r1Y140H constructs (Fig. 3) as well as Immu-
noﬂuorescence microscopy on the over-expressing ACHN cell lines
using a pp32r1 speciﬁc antibody (Supplementary Fig. 2). The observed
differential localization between pp32 and pp32r1 would suggest alter-
nate interaction partners and resulting downstream effects and is likely
to be one factor that inﬂuences the diametrically opposing functions
of these proteins as either tumor suppressor or oncogene respectively.
We cannot however exclude the possibility that nuclear pp32r1 or
pp32r1Y140Hmight exist. However any nuclear pp32r1would however
rely on co-transport alongside endogenous levels of pp32r1 binding
partners containing a bone-ﬁde NLS sequence that is clearly absent in
pp32r1.
Cells over-expressing pp32r1Y140H are known to have a signiﬁ-
cantly higher proliferation rate compared to control cells or cells
over-expressing pp32r1 [3]. Growth assays demonstrated that
overexpression of pp32r1 or pp32r1Y140H mutant protein in the
two p53wt cell lines (ACHN and HeLa) showed pronounced increases
in proliferation while in the transduced p53R248WMiaPaCa2 cell lines
no difference in cell growth was observed (Fig. 1b). The cell growth
differences observed for ACHN cells were much more prominent
than in HeLa cells. We hypothesize that this is likely to be deter-
mined by the normal cell doubling time of the untransduced ACHN
(28–30 h) and HeLa (23–24 h) cell lines. While the transduced
ACHN cell lines are able to accelerate their growth more toward the
limit of cell doubling time, HeLa cells are already an extremely fast
growing cell line very close to their cell doubling time limit. The ob-
servation that MiaPaCa2 cell growth was not affected highlighted a
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common p53R248W mutation abolishes p53 dependent p21 expres-
sion. Although it is possible that mutations in other genes could
play a role in modulating the pp32r1 induced proliferative capacity
of cells, these data strongly suggested that inﬂuence on p53 induced
p21 expression might be the predominant cause.
We investigated further both the cell cycle and proteomic differ-
ences in our ACHN cell lines. Cell cycle analysis of total DNA content
(PI staining) demonstrated a 2 fold increase in the S phase of
pp32r1Y140H over-expressing cells when compared to control or
pp32r1 expressing cells (Fig. 2a,c,e). A comparative quantiﬁcation of
the cells in S phase using the BrdU incorporation assay conﬁrmed
these data and we observed a 2 fold increase in the percentage of S
phase cells over-expressing the pp32r1Y140H mutant compared to
untransduced cells (Fig. 2b, d, f). These results suggested that the in-
crease in cell proliferation observed in the pp32r1Y140H mutant was
due to a dysfunctional control over the G1/S transition phase of the
cell cycle.
To understand the effects of pp32r1 and pp32r1Y140H over-
expression on the cell proteome we performed mass spectrometry
based whole proteome proﬁling on our 3 ACHN cell lines using the
ICPL technique. A total of 129 differentially regulated proteins were
identiﬁed with respect to control or pp32r1 transduced cells from
which we selected 13 highly regulated (>40%) proteins (Table 1). Sev-
eral of the proteinswe identiﬁed using the ICPL strategy have attributed
oncogenic roles and dysregulation can lead to Epithelial to Mesenchy-
mal transition (EMT), metastasis, multi drug resistance, cell survival
signalling, DNA repair, cell cycle regulation and overall poor prognosis
of cancer inﬂicted patients, a full description of the oncogenic roles
for all of these proteins is provided (Supplementary ICPL proteins.doc).
The CAPG and CHD4 proteins showed more than 1.5 fold
upregulation and were selected to validate the results of the ICPL by
QRTPCR and western blotting. The mRNA levels of both CHD4 and
CAPGwere found to beunaffected across the 3 ACHN cell lines; however
the protein levels of CHD4 and CAPG were found to be upregulated
in accordance with the ICPL data.
Macrophage Capping protein (CapG), a member of the gelsolin
superfamily of actin-binding proteins, which are crucial for the organi-
zation of the actin cytoskeleton. The actin cytoskeleton underlies many
cellular functions including the maintenance and mutability of cell
shape, motility, adherence, and growth regulation. Dysregulation
of actin-based motility is a prominent factor in cell transformation
and has been associated with carcinogenesis. Experimental evidence
shows that CapG known to be crucial for regulating cell motility
possesses an oncogenic function involved in the control of cell migra-
tion or invasion [17]. Signiﬁcant over expression of CapG was detected
in Oral Squamous Cell Carcinomas (OSCCs), Endometrial carcinomaFig. 4. Validation of ICPL data: Determination of CAPG/CHD4 mRNA and protein expression
levels quantiﬁed by real time PCR. Expression levels are normalized to a GAPDH control an
CAPG/CHD4 protein levels by western blotting of cell extracts, the housekeeping protein G(EmCa), Pancreatic Ductal Carcinoma, Prostate cancer through immu-
nohistochemical, LC-MS/MS, 2-DE/MS studies. Thus, enhanced expres-
sion of CapG has been associated with malignancy, increased tumor
size and reduced survival [17–20].
Chromodomain Helicase DNA binding protein 4 (CHD4) functions in
the coordination of DNA Damage Response (DDR) by mediating rapid
poly (ADP-ribose) dependent recruitment of the NuRD complex to
DNA damage sites [21]. Knockdown studies and BrdU incorporation
assays demonstrated a speciﬁc role of CHD4 in cell cycle progression,
in particular as a critical regulator of the G1 to S (G1/S) transition
through the control of p53 deacetylation [21,22]. This role of CHD4
further corroborated our observation of an elevated S phase in pp32r1
and pp32r1 Y140H over expressing cells.
The elevated levels of CHD4 and S phase cells caused by pp32r1 or
pp32r1Y140H over-expression suggested that CHD4 control of the
G1/S transition phase of the cell cycle had been dysregulated. The
major role of CHD4 is in the coordination of the DNA Damage
Response (DDR) however it is also known to inﬂuence the p53–p21
axis of the cell cycle, that acts as the master regulator of the G1/S
phase transition through p53 stabilization (via Lys-382 acetylation)
and subsequent induction of p53 dependent p21 transcription [15].
We therefore compared the cell cycle proﬁles and the levels of the
G1/S phase cell cycle checkpoint proteins Rb, p53, p21, cyclinE and
cyclinD1, across ACHN, ACHN pp32r1/pp32r1Y140H and CHD4
knockdown cells by western blotting. In cell lines overexpressing
pp32r1 or pp32r1Y140H we observed no difference in the levels of
Rb or CyclinE, while signiﬁcant increases were detected in CHD4
and p21 protein levels (Table 1 and Figs. 4b and 5b). In contrast
there was a modest decrease in the level of acetylated p53
(p53Ac382, stabilized form of p53).
CHD4 shRNA mediated knockdown in pp23r1Y140H over-
expressing cells demonstrated an approximate 80% reduction in S
phase cells thereby reverting the cell cycle proﬁle to that of the
untransduced ACHN cells and conﬁrming the relevance of CHD4 in
mediating the G1/S phase dysregulation in pp32r1Y140H over-
expressing cells. As predicted reduced CHD4 protein levels in CHD4
knockdown cells corresponded to a concomitant increase in
p53Ac382 levels, however, p21 levels still remained elevated despite
the CHD4 knockdown (Fig. 6b). At the mRNA level, negligible differ-
ences were seen in case of p53. However, both of the transduced
pp32r1/pp32r1Y140H overexpressing cell lines showed decreased
p21 levels with respect to ACHN. Similar RNA proﬁles for p53 and
p21 were obtained in CHD4 knockdown cells when compared with
the vector and scrambled controls (Figs. 5a and 6a).
The increased levels of p21 protein observed in our pp32r1 and
pp32r1YH overexpressing cell lines are consistent with clinical
data. Elevated levels of p21 expression have been detected inlevels across the ACHN, ACHN pp32r1 and ACHN pp32r1Y140H cell lines. (a) mRNA
d presented as levels relative to the ACHN cell line (set to 1.0). (b) Determination of
APDH was used as loading control.
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bladder carcinomas as well as malignantly transformed cell lines. In
these instances p21 contributes to a post-transcriptional and p53
independent mechanism of cell proliferation that is mediated via
cyclinD1 stabilization [39,23]. This is contrary to the assumption
that cyclin-dependent kinase inhibitors (CKIs) like p21 are solely
negative regulators of cyclin-dependent kinases (CDKs) and can
only contribute to cell cycle arrest. Interestingly, they can also be
found in complexes with active cyclin-CDKs allowing them to act
as positive regulators of the cell cycle [24]. Indeed p21 is an essential
activator of CDK4 and can increase the assembly and stability of
active cyclinD1-CDK4 complexes by promoting their localization to
the nucleus [41]. The increased levels of cyclinD1 and p21 in the
ACHN pp32r1, and ACHN pp32r1 Y140H cell lines appears consistent
with the ﬁndings of Coleman et al. who demonstrated that Ras
transformed ﬁbroblasts contain elevated levels of p21 and cyclinD1
and that p21 is responsible for stabilization and prevention of
cyclinD1 degradation by the 20S proteasome [24]. However, onFig. 5. Determination of mRNA and Protein levels of cell cycle regulatory proteins
across the ACHN, ACHN pp32r1/pp32r1Y140H cell lines: (a) mRNA levels of p53 and
p21 quantiﬁed by real time PCR. Expression levels are normalized to a GAPDH control
and presented as levels relative to the ACHN cell line (set to 1.0). (b) Determination of
Rb/P-Rb, p53 (K382ac), p21, CyclinD1 and CyclinE protein levels by western blotting of
cell extracts, the housekeeping protein GAPDH was used as loading control.silencing CHD4 in our ACHN pp32r1Y140H cell line the levels of
p21 were further increased, whereas no differences were observed
in the level of CyclinD1.
These increases in p21 have also been observed in the work
of Polo et al. where CHD4 knockdown in U2OS cells resulted in
a rapid accumulation of p21 protein that was restricted to p53
containing cells [15]. In these cells increases in p21 were accom-
panied by higher p53 protein levels and increased binding of p53
to the p21 promoter. Our CHD4 knockdown cells also illustrate
increases in p53Ac382 and p21, presumably like in U2OS cells
where p53-dependent transcriptional regulation of p21 occurs
as a result of DNA damage accumulation in CHD4 knockdown cells.Fig. 6. Determination of mRNA and protein levels of cell cycle regulatory proteins
across CHD4 shRNA knockdown cell lines (ACHNpp32r1Y140H) — empty vector,
scrambled (scr), shRNA#1 and shRNA#1+#2 transfected: (a) mRNA levels of p53
and p21 quantiﬁed by real time PCR. Expression levels are normalized to a GAPDH con-
trol and presented as levels relative to the ACHN pp32r1Y140H empty vector
transfected cell line (set to 1.0). (b) Determination of Rb/P-Rb, p53 (K382ac), p21,
CyclinD1 and CyclinE protein levels by western blotting of cell extracts, the housekeep-
ing protein GAPDH was used as loading control.
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was observed (Figs. 5b and 6b).This appears inconsistent with the
notion that p21, when is present above a certain threshold, can
negatively regulate cyclinE/Cdk2, resulting in lower levels of cyclinE
[25]. In our cell lines the negative regulation caused by an increase in
p21 levels appears to be off set by its regulation of cyclinD1, leading
to an over proliferative phenotype despite increased p21 expression
levels.
In summary our data suggests that pp32r1 and its functional
mutant Y140H can promote a CHD4 mediated cyclinD1 regulation
that causes p21 protein stabilization and leads to a maintained pro-
liferation of cells despite a dysregulation of the normal checkpoint
control mechanisms. Although we have focused on the effects
of the pp32r1Y140H mutation, further mutations exist in pp32r1
(e.g. E166G) identiﬁed in oral carcinoma [26] that appear to illus-
trate a similar phenotype. Although the prevalence of mutations in
clinical cases is still unclear such a phenotype may have implications
on patient treatment scenarios. Indeed we have also observed signif-
icant differences in the viability of pp32r1 or pp32r1 mutant cell
lines in response to certain chemotherapeutic agents (Unpublished
Observations).
The pp32 family proteins have functional roles in the essential
cellular processes of transcription, mRNA export, apoptosis, and
cell cycle regulation. These functional roles can be impaired as is
seen by their involvement in both cancer [27–29,7,30] and neurode-
generative diseases like spinocerebellar ataxia type 1 [31], high-
lighting the important role they play inmaintaining cellular stability.
Supplementary data to this article can be found online at http://
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